BridgeMD
New treatment option for Carpal Tunnel Syndrome
Official title Effect of Night-time and Full-time Splinting for Carpal Tunnel Syndrome
ClinicalTrials.gov ID: NCT05637294
What this study is testing
- What it's testing
- Carpal tunnel syndrome is a common compression neuropathy of upper extremities. Its usual symptoms are pain, numbness and tingling of fingers, which tend to be worse at night.
- Time commitment: about 24 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Clinically confirmed carpal tunnel syndrome (CTS) of any severity level (diagnostic criteria: numbness, pain or paraesthesia in the median nerve...
- Symptom duration of CTS for at least 3 weeks,
- No previous corticosteroid injection for CTS during last 6 months,
- No previous surgery for CTS,
- Aged 18 years or older,
You likely can't join if
- Nerve root or plexus disorders that might be causing CTS mimicking symptoms (e.g., cervical radiculopathy, thoracic outlet syndrome, or whiplash...
- Other neurological condition affecting the function of the hand such as Multiple Sclerosis, previous nerve injury,
- Active Rheumatoid arthritis or any other active inflammatory joint disease affecting the hand,
- Thenar muscle atrophy,
- Untreated hypothyroidism,
- Known allergy to any of the splint materials (self-reported by patient),
See the full eligibility criteria
- Clinically confirmed carpal tunnel syndrome (CTS) of any severity level (diagnostic criteria: numbness, pain or paraesthesia in the median nerve distribution area of wrist and fingers),
- Symptom duration of CTS for at least 3 weeks,
- No previous corticosteroid injection for CTS during last 6 months,
- No previous surgery for CTS,
- Aged 18 years or older,
- Able to complete self-report questionnaires electronically,
- Able to understand Finnish,
- Willing to join the study and follow the study protocol instructions,
- Sign informed consent.
- Nerve root or plexus disorders that might be causing CTS mimicking symptoms (e.g., cervical radiculopathy, thoracic outlet syndrome, or whiplash associated disorders),
- Other neurological condition affecting the function of the hand such as Multiple Sclerosis, previous nerve injury,
- Active Rheumatoid arthritis or any other active inflammatory joint disease affecting the hand,
- Thenar muscle atrophy,
- Untreated hypothyroidism,
- Known allergy to any of the splint materials (self-reported by patient),
- Long term treatment (over 4 months) for CTS with no response,
- Any other known reason that could prevent from participation for the study time.
The study team makes the final eligibility decision.
Where it's taking place
- Helsinki, Finland
- Jyväskylä, Finland
- Mikkeli, Finland
- Tampere, Finland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 24 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Helsinki, Finland; Jyväskylä, Finland; Mikkeli, Finland; Tampere, Finland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.